Technical Articles

P53 突变:从守护者到失守,如何改写肿瘤治疗叙事?
P53 in Biopharma: From a 40-Year Drug Hunt to Reagent Standardization
发布时间 2026-10-10
Why P53 has driven four decades of drug discovery yet remains unsolved, and how standardized recombinant P53 reagents support target validation, screening and mechanistic studies across the industry.
View details
  • Cancer
  • P53
  • TP53 drug discovery
  • targeted therapy
  • PROTAC
  • reagent standardization
  • UA085067
Total 1
  • 1
Go to